Raphael R.

Raphael R. serves as CEO and Chairman of the Board of Directors at Antharis Therapeutics, Inc. since April 2020, and also holds the title of Advisory Board Member at Aeterna Therapeutics since 2024. In addition, Raphael R. is CEO and Chairman of the Board of Directors at Galileo Biotech, which was acquired by Antharis Therapeutics in August 2023. Raphael R. leads Pinaud Investments as CEO & Executive Chairman and has been a Partner & Portfolio Manager at Leste Global Investments since May 2014. Further involvement includes serving as a Board Member for Cassyni Biopharma and Piauhy Labs, along with multiple advisory roles at MEDLYTICS, Tillat Pharmaceuticals, and Kinlio. Educational credentials include an MBA in Economics and Strategic Business Management from Harvard Business School, a Post-Doc in Biomedical Engineering/Proteomics from Duke University, a PhD in Neuroscience from Oregon Health & Science University, an MSc in Molecular Biology/Neuroscience from Dalhousie University, and a BSc in Biological Sciences/Genetics from the Federal University of Rio de Janeiro.